Show simple item record

dc.contributor.authorFernández Tussy, Pablo
dc.contributor.authorFernández Ramos, David
dc.contributor.authorLopitz Otsoa, Fernando
dc.contributor.authorSimon, Jorge
dc.contributor.authorBarbier Torres, Lucía
dc.contributor.authorGómez Santos, Beatriz
dc.contributor.authorNuñez García, Maitane
dc.contributor.authorAzkargorta, Mikel
dc.contributor.authorSerrano Maciá, Marina
dc.contributor.authorGutiérrez de Juan, Virginia
dc.contributor.authorSerrano Maciá, Marina
dc.contributor.authorRodríguez Agudo, Rubén
dc.contributor.authorIruzubieta, Paula
dc.contributor.authorAnguita Castillo, Juan de Dios
dc.contributor.authorCastro, Rui E.
dc.contributor.authorChampagne, Devin
dc.contributor.authorRincon, Mercedes
dc.contributor.authorElortza, Felix
dc.contributor.authorArslanow, Anita
dc.contributor.authorKrawczyk, Marcin
dc.contributor.authorLammert, Frank
dc.contributor.authorKirchmeyer, Melanie
dc.contributor.authorBehrmann, Iris
dc.contributor.authorCrespo, Javier
dc.contributor.authorLu, Shelly C.
dc.contributor.authorMato, José M.
dc.contributor.authorVarela Rey, Marta
dc.contributor.authorAspichueta Celaá, Patricia
dc.contributor.authorDelgado, Teresa C.
dc.contributor.authorMartínez Chantar, María Luz ORCID
dc.date.accessioned2020-01-29T09:33:55Z
dc.date.available2020-01-29T09:33:55Z
dc.date.issued2019-08-16
dc.identifier.citationMolecular Metabolism 29 : 40-54 (2019)es_ES
dc.identifier.issn2212-8778
dc.identifier.urihttp://hdl.handle.net/10810/39225
dc.description.abstractObjective: Non-alcoholic fatly liver disease (NAFLD) is a complex pathology in which several dysfunctions, including alterations in metabolic pathways, mitochondrial functionality and unbalanced lipid import/export, lead to lipid accumulation and progression to inflammation and fibrosis. The enzyme glycine N-methyltransferase (GNMT), the most important enzyme implicated in S-adenosylmethionine catabolism in the liver, is downregulated during NAFLD progression. We have studied the mechanism involved in GNMT downregulation by its repressor microRNA miR-873-5p and the metabolic pathways affected in NAFLD as well as the benefit of recovery GNMT expression. Methods: miR-873-5p and GNMT expression were evaluated in liver biopsies of NAFLD/NASH patients. Different in vitro and in vivo NAFLD murine models were used to assess miR-873-5p/GNMT involvement in fatty liver progression through targeting of the miR-873-5p as NAFLD therapy. Results: We describe a new function of GNMT as an essential regulator of Complex II activity in the electron transport chain in the mitochondria. In NAFLD, GNMT expression is controlled by miR-873-5p in the hepatocytes, leading to disruptions in mitochondria! functionality in a preclinical murine non-alcoholic steatohepatitis (NASH) model. Upregulation of miR-873-5p is shown in the liver of NAFLD/NASH patients, correlating with hepatic GNMT depletion. Importantly, NASH therapies based on anti-miR-873-5p resolve lipid accumulation, inflammation and fibrosis by enhancing fatty acid beta-oxidation in the mitochondria. Therefore, miR-873-5p inhibitor emerges as a potential tool for NASH treatment. Conclusion: GNMT participates in the regulation of metabolic pathways and mitochondria! functionality through the regulation of Complex II activity in the electron transport chain. In NAFLD, GNMT is repressed by miR-873-5p and its targeting arises as a valuable therapeutic option for treatment. (C) 2019 The Authors. Published by Elsevier GmbH.es_ES
dc.description.sponsorshipThis work was supported by grants from NIH (US Department of Health and Human services)-R01AT001576 (to S.C.L., J.M.M., and M.L.M.-C.), Ministerio de Economia, Industria y Competitividad: SAF2017-87301-R (to M.L.M.-C.), SAF2015-64352-R (to P.A.), Gobierno Vasco-Departamento de Salud 2013111114 (to M.L.M.-C.), Gobierno Vasco-Departamento de Educacion IT-336-10 (to PA), BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15/CA/016/BD (M.L.M.-C.), ELKARTEK 2016, Departamento de Industria del Gobierno Vasco (to M.L.M.-C), Asociacion Espanola contra el Cancer (to T.C.D., P.F.-T. and M.L.M.-C.), Mitotherapeutix (to M.L.M.-C.), Daniel Alagille award from EASL (to T.C.D), Fundacion Cientifica de la Asociacion Espanola Contra el Cancer (AECC Scientific Foundation) Rare Tumor Calls 2017 (to M.L.M.-C.), La Caixa Foundation Program (to M.L.M.-C.), Ayudas Fundacion BBVA a Equipos de Investigacion Cientifica 2019 (to M.L.M.-C.). Ciberehd_ISCIII_MINECO is funded by the Instituto de Salud Carlos III. We thank this work produced with the support of a 2017 Leonardo Grant for Researchers and Cultural Creators, BBVA Foundation (to M.V.R.). This work was supported by Fonds National de la Recherche Luxembourg and the Deutsche Forschungsgemeinschaft (C12/BM/3975937, FL/997/7-1, Inter "HepmiRSTAT", to I.B. and F.L.). We thank MINECO for the Severo Ochoa Excellence Accreditation (SEV2016-0644).es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/SAF2017-87301-Res_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/SAF2015-64352-Res_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/SEV2016-0644es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectnashes_ES
dc.subjectgnmtes_ES
dc.subjectmitochondriaes_ES
dc.subjectbeta-oxidationes_ES
dc.subjectmetabolismes_ES
dc.subjectmicrornaes_ES
dc.subjectglycine-n-methyltransferasees_ES
dc.subjecthepatocellular-carcinomaes_ES
dc.subjectgene-expressiones_ES
dc.subjectsteatohepatitises_ES
dc.subjectsteatosises_ES
dc.subjectphosphatidylethanolaminees_ES
dc.subjectneddylationes_ES
dc.subjectdysfunctiones_ES
dc.subjectlipogenesises_ES
dc.subjectmetabolismes_ES
dc.titlemiR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver diseasees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© 2019 The Authors. Published by Elsevier GmbH. This article is available under the Creative Commons CC-BY-NC-ND license and permits non-commercial use of the work as published, without adaptation or alteration provided the work is fully attributed.es_ES
dc.rights.holderAtribución-NoComercial-SinDerivadas 3.0 España*
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S2212877819306209?via%3Dihubes_ES
dc.departamentoesFisiologíaes_ES
dc.departamentoeuFisiologiaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2019 The Authors. Published by Elsevier GmbH. This article is available under the Creative Commons CC-BY-NC-ND license and permits non-commercial use of the work as published, without adaptation or alteration provided the work is fully attributed.
Except where otherwise noted, this item's license is described as © 2019 The Authors. Published by Elsevier GmbH. This article is available under the Creative Commons CC-BY-NC-ND license and permits non-commercial use of the work as published, without adaptation or alteration provided the work is fully attributed.